HKSE:1513

Livzon Pharmaceutical Group Inc. · HKSE · Healthcare · HKD · FY for 2024

Figures on this page computed 2026-11-08 13:27 UTC

Last close

n/aHKD

Market data

9.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2024
33.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
17.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
20.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
0.28Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

What it pays out is the furthest below its sector's middle: 0.30 against 0.54 on the market's range.

Follow one yuan

lens 1 of 9

After what it costs to make

65.5%

After running the business

24.1%

After interest and tax

17.5%

After what it must reinvest

20.4%

Kept after the dividend

9.0%

after what it costs to make, 65.5% of sales; after running the business, 24.1% of sales; after interest and tax, 17.4% of sales; after what it must reinvest, 20.4% of sales; kept after the dividend, 9.0% of sales

The five stops

5 of 5 read

After what it costs to make7,731,231,89865.5%
After running the business2,844,400,26124.1%
After interest and tax2,061,095,80317.5%
After what it must reinvest2,408,691,83320.4%
Kept after the dividend1,068,385,2389.0%

Of every unit of sales, 0.09 is still there after the dividend.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2024

Sales11,812,338,854
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
After what it costs to make7,731,231,898
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
After running the business2,844,400,261
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
After interest and tax2,061,095,803
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
After what it must reinvest2,408,691,833
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
Kept after the dividend1,068,385,237.7
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY